ATLANTA--(BUSINESS WIRE)--CardioMEMS, Inc., the pioneer in wireless sensing for the management of chronic cardiovascular diseases such as Heart Failure, today announced the closing of its Series E Preferred Stock financing for $33 million of equity funding led by Arcapita Ventures. Joining Arcapita in this financing round are existing investors Boston Millennia Partners, Medtronic, Inc., Easton Capital Partners, Foundation Medical Partners, and Arboretum Ventures, along with new investors Deerfield Capital Management, Vision Capital Advisors, Aperture Venture Partners and Rockport Venture Securities.
